Bronchogen
Lab-Tested ≥98% Purity · Certificate of Analysis Included · Global Shipping
Bronchogen (Ala-Glu-Asp) — Bronchial Bioregulator Peptide for Pulmonary Research
Bronchogen is a synthetic tripeptide bioregulator (Ala-Glu-Asp) developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson. This short peptide belongs to the Khavinson class of tissue-specific bioregulators that modulate gene expression through direct DNA interaction. Bronchogen has been specifically characterized for its regulatory effects on bronchial mucosa and respiratory epithelium, with research published in Bulletin of Experimental Biology and Medicine documenting its capacity to normalize respiratory tissue function in aged and compromised animal models.
Mechanism of Action
Bronchogen interacts with specific nucleotide sequences in promoter regions of genes expressed in bronchial epithelial tissue. This short bioregulator peptide penetrates cell membranes and binds the minor groove of double-stranded DNA, modulating chromatin accessibility and transcription factor binding at target gene loci. Research has demonstrated that Bronchogen upregulates the expression of surfactant proteins (SP-A, SP-D), mucin regulatory genes, and anti-inflammatory mediators in bronchial tissue cultures, while normalizing ciliary beat frequency in airway epithelial cell monolayers.
Key Research Areas
- Bronchial Epithelial Regeneration: Studies on human bronchial epithelial cell cultures have demonstrated that Bronchogen enhances proliferative capacity and restores tight junction protein expression (claudin-1, occludin) following chemical injury, suggesting accelerated mucosal barrier repair.
- Mucociliary Function: Research in aged murine respiratory explants has shown normalization of ciliary beat frequency and mucus transport velocity following Bronchogen treatment, restoring parameters to levels observed in young control tissue.
- Anti-Inflammatory Modulation: In-vitro studies have documented reduced IL-8 and TNF-α secretion from LPS-stimulated bronchial epithelial cells treated with Bronchogen, while preserving baseline immune surveillance capacity.
- Age-Related Pulmonary Decline: Long-term studies in aged rodent models have observed preserved alveolar architecture and maintained gas exchange efficiency, with histological analysis showing reduced emphysematous changes compared to untreated controls.
Technical Specifications
- Dosage per vial: 10mg lyophilized powder
- Purity: ≥98% (HPLC verified)
- Sequence: Ala-Glu-Asp (AED tripeptide)
- Molecular Weight: 333.29 Da
- Storage: -20°C, protected from light
Why Researchers Choose Peptides BioLab
Every batch of Bronchogen supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our product is supplied as a lyophilized powder for maximum stability, shipped worldwide in temperature-controlled packaging.
Related Research Peptides
Researchers studying Khavinson bioregulators and tissue repair may also find these compounds relevant: Thymalin, BPC-157, and KPV. For a complete overview, browse our Recovery Research collection.
For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.
Every Peptides BioLab product includes a Certificate of Analysis (CoA) with HPLC and MS data confirming ≥98% purity. The CoA is available in the product tabs as the 2nd image, or contact our team to request a copy.
Shipping: We ship worldwide from our state-of-the-art facilities. Orders are processed within 1–2 business days. Express and standard shipping options available at checkout.
Storage: Store lyophilized peptides at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 30 days. Keep away from direct sunlight.
